scholarly journals A Case of Esophageal Cancer with Lymph Node Recurrence Three Times and Secondary Cancer after Definitive Chemoradiotherapy

2018 ◽  
Vol 79 (1) ◽  
pp. 84-89
Author(s):  
Yayoi SAKATOKU ◽  
Masahide FUKAYA ◽  
Kazushi MIYATA ◽  
Takamasa TAKAHASHI ◽  
Masato NAGINO
Keyword(s):  
Esophageal Cancer ◽  
Lymph Node ◽  
Secondary Cancer ◽  
Definitive Chemoradiotherapy ◽  
Lymph Node Recurrence

PS02.031: DEFINITIVE CHEMORADIOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL (DCF-R) FOR ADVANCED CERVICAL ESOPHAGEAL CANCER

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 128-129
Author(s):  
Hiroshi Okamoto ◽  
Yusuke Taniyama ◽  
Tadashi Sakurai ◽  
Takahiro Heishi ◽  
Chiaki Sato ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Cancer ◽  
Lymph Node ◽  
Survival Rate ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Conflicts Of Interest ◽  
Clinical Stage ◽  
Stage Ii ◽  
Definitive Chemoradiotherapy

Abstract Background Recently, definitive chemoradiotherapy (dCRT) has become one of the essential treatment strategies for esophageal squamous cell carcinoma (ESCC) and has been especially gaining prevalence for cervical ESCC to preserve the larynx. There have been recent reports on favorable outcomes of docetaxel/CDDP/5-FU (DCF-R) for advanced esophageal cancer. Our department recently introduced DCF-R for treating advanced cervical ESCC. We analyzed the safety and outcomes of DCF-R in patients with advanced cervical ESCC. Methods We retrospectively evaluated 12 advanced cervical ESCC patients (clinical stage II–IV, including T4b and/or M1 lymph node) in our department who received DCF-R as the first-line treatment between December 2010 and February 2015. Results Our patient cohort comprised 9 males and 3 females (median age, 67.5 years; range: 54–76 years). All patients were squamous cell carcinoma. The median observation period was 34.5 (8–80) months with total irradiation dose of 64.0 (60–70) Gy. The pretreatment clinical stage (according to Union for International Cancer Center) included one stage II, seven stage III, and four stage IV cases (including 3 patients with T4b [2 trachea and 1 thyroid] and 4 patients with M1 lymph node. We attained complete response (CR) in 10 patients and stable disease in 2 patients. Of 10 patients with CR, 5 experienced recurrence and 5 continued exhibiting CR. Two persistent patients included one patient who died of cancer and one patient who underwent salvage surgery. Furthermore, grade 3 or more adverse events as defined in Common Terminology Criteria for Adverse Event version 4 included leucopenia (91.7%), neutropenia (91.7%), febrile neutropenia (50%), and pharyngeal pain (50%). There was no treatment-related mortality and treatment schedules were completed in all patients, although dose reduction of the second cycle of chemotherapy was required in four patients (33%) and change in the radiation schedule was required in one patient (8.3%). While the 2-/3-/5-year overall survival rate was 66.7%/48.6%/48.6%, the 2-/3-/5-year recurrent-free survival rate was 58.3%/50.0%/37.5%, respectively. Conclusion DCF-R treatment for advanced cervical ESCC could be completed by the careful administration, and although a strong blood toxicity might occur, a favorable prognosis can be obtained with larynx preservation. Disclosure All authors have declared no conflicts of interest.

scholarly journals 18F-FAMT-PET Is Useful for Judging Clinical Complete Response in Advanced Esophageal Cancer Patients Who Have Received Definitive Chemoradiotherapy

2019 ◽  
Vol 103 (11-12) ◽  
pp. 561-566
Author(s):  
Makoto Sohda ◽  
Hiroaki Honjyo ◽  
Keigo Hara ◽  
Daigo Ozawa ◽  
Shigemasa Suzuki ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Node ◽  
Fdg Pet ◽  
Complete Response ◽  
Mediastinal Lymphadenopathy ◽  
Definitive Chemoradiotherapy ◽  
Primary Tumors ◽  
Fdg Uptake ◽  
Positron Emission ◽  
Node Metastases

We developed l-[3-18F]-α-methyltyrosine (18F-FAMT) as an amino acid tracer for positron emission tomography (PET) imaging. In esophageal cancer, the specificity of 18F-FAMT PET was significantly higher than that of fluoro-2-deoxy-d-glucose (18F-FDG) PET and computed tomography (CT) in the evaluation of individual lymph node groups. Definitive chemoradiotherapy (CRT) has been considered a potentially curative treatment for locoregional esophageal cancer and may achieve the same survival benefits as surgical resection. Clinical evaluation of complete response (CR) is important using several modalities. We evaluated 6 patients who had been diagnosed with clinical CR by FAMT-PET following definitive CRT for esophageal squamous cell carcinoma between June 2008 and July 2012. Treatment evaluation of 18F-FAMT was performed following CRT and approximately 1 month later. In primary tumors, 66.7% of patients (4/6) showed FDG uptake following CRT, whereas that of FAMT was 33.3% (2/6). In lymph node metastases, 50% of patients (3/6) showed FDG uptake following CRT, whereas that of FAMT was 0% (0/6). In the present study, FAMT-PET following CRT was a useful modality to predict clinical CR in esophageal cancer. There is a limit to judging clinical CR by CT or FDG-PET following CRT, because radiation-related esophagitis and reactive mediastinal lymphadenopathy by FDG and wall thickness by CT still remain 1 month following CRT. FAMT-PET is the most useful modality at the present time.

Lymphadenectomy via a cervical approach for upper mediastinal lymph node recurrence of esophageal cancer: Report of a case

Surgery Today ◽  
2011 ◽  
Vol 41 (11) ◽  
pp. 1562-1566 ◽  
Author(s):  
Hiroyuki Tada ◽  
Atsushi Shiozaki ◽  
Hitoshi Fujiwara ◽  
Daisuke Ichikawa ◽  
Kazuma Okamoto ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Node ◽  
Mediastinal Lymph Node ◽  
Lymph Node Recurrence ◽  
Cervical Approach
Sign in / Sign up

Export Citation Format

Share Document